Category: Bipolar disorder

  • BioXcel gets first approval for agitation drug Igalmi

    BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder. Igalmi (dexmedetomidine) is the first drug to be approved for this use that is formulated as an tablet that dissolves under the tongue, and the first […]

  • After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi

    The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly genericised market. The US regulator approved Lybalvi (olanzapine/samidorphan) for both indications sought – schizophrenia and bipolar I disorder – with data on its […]

  • Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market

    Characterized by debilitating episodes of depression and mood elevation (mania or hypomania), Bipolar depression is an under-recognized and unappreciated phase of bipolar disorder. Since most patients exhibit depression, Bipolar depression gets misdiagnosed with other mental disorders easily. Thus, it is associated with a heavier burden of illness, morbidity, and cost. Even then, there is no […]